Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
Out-licensing Search
Search the Pharmalicensing out-licensing directory by keyword. Alternatively our advanced search allows you to query by industry sector, therapeutic target and development phase.
Most Viewed
Each Dose of Neo-Penotran® contains a combination of Metronidazole and Miconazole Nitrate in therapeutic concentrations for the local treatment of the treatment three main types of vaginal infections and mixed forms of vaginitis. More
New cream formulation to manage the symptoms of atopic dermatitis. More
Collagen-based dressings for wound management More
25 and 50 mg diclofenac K film coated immediate release tablets More
Xclair is a cream, indicated for the management of radiation-induced dermatitis, including relief and management of the most common signs and symptoms such as pruritus, erythema, burning and pain. More
Recently Added
This project is based on several experimental findings that identify a Bcl-2 family protein as important for mast cell survival in allergic reactions. Inhibition of this protein leads to a decreased number of mast cells in inflamed tissue More
A new class of compounds with pure anti-estrogen activity has been identified. The compounds are structurally unique and possess higher affinity to the human estrogen receptor and exhibit a substantially increased oral bioavailability than faslodex. More
This project is based on the finding that a tyrosine kinase highly expressed in the pancreatic Islets of Langerhan is involved in cytokine induced beta-cell death. This tyrosine kinase has been biologically well validated as a novel drug target. More
A treatment regimen based on a newly discovered endogeneous fragment of Histidine-rich glycoprotein (HRGP). A 35mer peptide derived thereof has been identified and shown to significantly inhibit tumor vascularization and growth of experimental tumors More
Collagen-based adhesion barrier for the prevention of surgical adhesions More
Help & Support
Find out how to use this section.
View the presentation.
View the presentation.
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Therapeutic target
- Accident and Trauma
- Allergy
- Blood and forming organs
- Cardiovascular
- Central Nervous System
- Dermatological
- Endocrinology
- Gastrointestinal
- Genetic disorders
- Genito-urinary
- Hospital and Surgery
- Immune related disorders
- Infectious diseases
- Metabolism
- Musculoskeletal
- Oncology
- Oral Health
- Other therapeutic
- Respiratory
- Sensory organ
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
In the Spotlight...
Chemeq Technologies
Chemeq Technologies Pty Ltd is an innovative research company offering a unique antimicrobial polymer which provides a safe and effective alternative to antibiotics and conventional antimicrobials for human healthcare
The company's unique class-leading technology which is protected by seven major worldwide international patents has a wide application for therapeutic purposes for both topical and gastrointestinal indications
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us